本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Poseida Therapeutics, Inc.

9.50
0.0000
成交量:- -
成交额:2.04亿
市值:9.29亿
市盈率:-14.95
高:9.50
开:9.50
低:9.50
收:9.50
数据加载中...
2025/01/08

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2025/01/08

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2025/01/08

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2025/01/08

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2025/01/08

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2025/01/08

交易所摘牌声明

Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities
2025/01/08

重要事件披露

Form 8-K - Current report
2024/12/27

SEC问询函

Form CORRESP - Correspondence
2024/11/27

超过5%披露

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
2024/11/26

关联方拟减持公告

Form 144 | POSEIDA THERAPEUTICS INC 高管 Mark Gergen 拟减持120000股,总价约34.32万美元
2024/11/26

重要事件披露

Form 8-K - Current report
2024/11/14

重要事件披露

Form 8-K - Current report
2024/11/07

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/11/07

重要事件披露

Form 8-K - Current report
2024/09/30

重要事件披露

Form 8-K - Current report
2024/08/12

SEC问询函

Form CORRESP - Correspondence
2024/08/05

重要事件披露

Form 8-K - Current report
2024/08/05

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/06/18

重要事件披露

Form 8-K - Current report
2024/05/14

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]